Mark G. Kris, MD, Chair of the ASCO Cancer Communications Committee, commented at the press briefing that the study represents “an example of the evolution of targeted cancer therapies in that we are seeing early signs of benefit by going after multiple targets in the cancer cell. We saw important tumor shrinkage that translated into stronger bones and less pain from bony metastases,” he said. ■

Financial Disclosure: Dr. Kris reported no potential conflicts of interest.